Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 18/20 | 0.40 |
| ▸ | CBL | P22681 | 15/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30374453 | 1.00 | CBLB (0.40) | CBLBCBLCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22832997 | 0.89 | CBLB (0.41) | CBLBCBLCBLC | |
| SCHEMBL30374080 | 0.87 | CBLB (0.44) | CBLBCBL | |
| SCHEMBL25179648 | 0.87 | CBLB (0.44) | CBLBCBL | |
| SCHEMBL32686461 | 0.86 | CBLB (0.40) | CBLBCBLCBLC | |
| SCHEMBL30373880 | 0.86 | CBLB (0.38) | CBLBCBLCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25183728 | 0.86 | CBLB (0.38) | CBLBCBLCHRNA1CHRNGCHRNB1 | |
| SCHEMBL24662646 | 0.85 | CBLB (0.41) | CBLBCBLCBLC | |
| SCHEMBL30374240 | 0.85 | CBLB (0.41) | CBLBCBLCBLC | |
| SCHEMBL32686435 | 0.85 | CBLB (0.42) | CBLBCBLCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023081853-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | GENENTECH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212153-A1 | LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL | CBL, CBLB, CBLC | CBLB 2/4885CBL 1/4885CHRNA1 4346/4885 |
| US-12187709-B2 | Lactams as CBL-B inhibitors selective over C-CBL | CBL, CBLB, CBLC | CBLB 2/4885CBL 1/4885CHRNA1 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.